IVO’s German play beats expectations

|

Published 21-APR-2016 10:43 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Invigor Group Limited’s (ASX:IVO) German acquisition, Condat, is doing better than expected – with both revenue and earnings above forecast.

The Berlin-based outfit has booked $2 million in revenue and $420,000 in earnings before tax for the first quarter of the year.

Both revenue and earnings are ahead of schedule – with IVO chairman Gary Cohen telling investors that the earnings figure was particularly pleasing.

“We are very pleased with the performance of Condat in the March quarter, being the first full quarter under Invigor’s ownership,” he said.

“The EBITDA margin of 21% is better than expected and provides further validation of Condat’s potential to Invigor in both the short and long term.”

The German company’s main product is its Smart Media Engine, which allows broadcasters to analyse ‘semantic content’ – and is being seen as a way to complement IVO’s existing big data analysis capabilities.

It also give IVO an entry into the lucrative European media market.

In further Condat news, it has emerged that the German media player has been selected to head up a consortium including the Agence France Presse and Deutsche Welle on a content verification system.

The project, dubbed the EU InVID project, will develop a platform capable of verifying the authenticity of emerging stories coming in over platforms such as YouTube, Twitter, or Instagram.

The end goal would be to integrate this capability into Condat’s smart media engine, which will be able to analyse and classify gathered media content for editing, curation, and playout.

About Invigor (ASX:IVO)

Invigor uses a complementary suite of big data products to source, aggregate, analyse and publish content for the benefit of businesses and consumers.

Its big data solutions helps retailers, brands, shopping centres and government bodies to identify and better understand competitors, consumers, markets and demographics while providing consumers with information that brings them to a decision about the best value-for-money purchase.

The big data industry as a whole is set to be worth $50 billion, and though some are frightened by its big brother-like power, it is here to stay.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X